Peptide therapy in Australia
Peptide therapy is the clinical use of short amino-acid chains — BPC-157, CJC-1295, Ipamorelin, tirzepatide, AOD-9604, MOTS-c — to support recovery, metabolic health, body composition, and growth-hormone signalling. In Australia it's prescribed lawfully by an AHPRA-registered doctor under the TGA Special Access Scheme Category B and dispensed by a TGA-licensed Australian compounding pharmacy.
$99 initial consult
Telehealth with an AHPRA-registered Australian doctor. Compounded peptide cost is additional and depends on molecule and dose.
Reviewed at 4 & 12 weeks
Peptide therapy isn't set-and-forget. Your prescriber reviews response, side effects, and dose at every checkpoint.
Lawful pathway
TGA SAS-B notification + TGA-licensed Australian compounding pharmacy. No offshore importing, no “research” vials.
What peptide therapy is used for
Tirzepatide (Mounjaro) and AOD-9604 are the main metabolic peptides prescribed in Australia for eligible patients.
BPC-157 and TB-500 are commonly used for soft-tissue injury, tendon, and gut-lining repair under SAS-B.
CJC-1295 + Ipamorelin support natural growth-hormone pulses, deeper sleep, and body composition.
How peptide therapy works, end-to-end
- 1. Free 5-minute pre-qualification
Quick eligibility check covering goals, history, and red flags. No payment until you're matched with a doctor.
- 2. $99 AHPRA telehealth consult
An Australian-registered doctor confirms suitability, chooses the molecule and dose, and lodges any required TGA SAS-B notification.
- 3. Australian-compounded vial dispensed
A TGA-licensed compounding pharmacy compounds your prescription under PIC/S GMP and cold-ships it Australia-wide.
- 4. 4-week and 12-week review
Your prescriber reviews response, adverse effects, and lab markers and adjusts or stops as clinically indicated.
Frequently asked questions — peptide therapy
- What is peptide therapy?
- Peptide therapy is the medical use of short chains of amino acids (peptides) — such as BPC-157, CJC-1295, Ipamorelin, AOD-9604, MOTS-c, or tirzepatide — to support tissue repair, metabolic health, body composition, sleep, or growth hormone signalling. In Australia it is prescribed by an AHPRA-registered doctor, typically under the TGA Special Access Scheme Category B, and dispensed by a TGA-licensed Australian compounding pharmacy.
- How much does peptide therapy cost in Australia?
- An initial telehealth consult with an AHPRA-registered Australian doctor is $99. Compounded peptide cost varies by molecule and dose: roughly AUD $180–$320/month for BPC-157, $220–$380 for CJC-1295 + Ipamorelin, and $450–$900+ for tirzepatide. Pathology, when needed, is bulk-billed where eligible. There are no separate dispensing or shipping fees from the Australian compounding pharmacy.
- Is peptide therapy safe?
- When prescribed by an AHPRA-registered Australian doctor and compounded by a TGA-licensed pharmacy under PIC/S GMP, peptide therapy has a well-characterised side-effect profile that your prescriber reviews at 4 and 12 weeks. Risk rises sharply if peptides are sourced from offshore "research chemical" vendors — those vials are not sterility-, identity-, or potency-tested, and there is no Australian doctor or pharmacy accountable for the outcome.
- How is peptide therapy administered?
- Most therapeutic peptides are administered as small-volume subcutaneous injections into abdominal fat with a 29–31G insulin syringe, once daily or several times per week depending on the molecule. Your doctor and pharmacy provide written and video instructions at first dispense. Some peptides (e.g. cosmetic GHK-Cu serums) are topical only and not part of the prescription-only category.
- Is peptide therapy FDA approved?
- The FDA is a US regulator and doesn't apply in Australia. In Australia the equivalent regulator is the TGA. A small number of peptide medicines are ARTG-registered (notably tirzepatide / Mounjaro and semaglutide / Ozempic for eligible patients). Most peptide-clinic medicines — BPC-157, CJC-1295, Ipamorelin, GHK-Cu injectable, MOTS-c, AOD-9604 — are not ARTG-registered as finished products and are prescribed lawfully via the TGA Special Access Scheme Category B.
- Does peptide therapy work?
- Evidence varies by molecule and goal. Tirzepatide and semaglutide have large randomised trials supporting weight loss in eligible patients. BPC-157 has strong preclinical and emerging clinical evidence for soft-tissue repair. CJC-1295 + Ipamorelin reliably raises growth-hormone pulses on lab markers. Your AHPRA-registered doctor matches the molecule to your goal and reviews response objectively at 4 and 12 weeks — peptide therapy isn't a guarantee, it's a clinical trial of one with measurable endpoints.
- Is peptide therapy legit?
- Peptide therapy delivered through an AHPRA-registered Australian doctor, lodged under TGA SAS-B, and dispensed by a TGA-licensed Australian compounding pharmacy is fully lawful and clinically governed. "Research peptide" websites that ship from offshore are not a legitimate medical pathway — they bypass prescriber oversight, pharmacy QA, and customs law.
Medically reviewed by the PeptideDoctorAU Medical Review Panel — last reviewed 29 May 2026. See the panel.
Start peptide therapy lawfully — $99 telehealth consult
Free 5-minute pre-qualification. If suitable, you'll be matched with an AHPRA-registered Australian doctor for a $99 telehealth consult — TGA SAS-B prescribing, Australian-compounded vial.
Start free assessment